Keio research program for severe asthma in Japanese population

Keio research program for severe asthma in Japanese population - Keio-SARP

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000002980

Enrollment

300

Registered

2010-01-25

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe asthma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A. Severe asthma group Satisfy any of 1-5 below 1. Oral steroid use for the treatment of asthma exacerbation during the past one year 2. FEV1 %predicted is below 60% at the stable state 3. Regular oral steroid use >50% of the past one year 4. High dose inhaled corticosteroid use (600 mcg or more of fluticasone or equivalent) 5. Diagnosed as severe asthma by physician B. Mild to moderate asthma None of 1-5 above Sex and gender are matched with severe asthma group

Exclusion criteria

Exclusion criteria: 1. diffuse lung lesion confirmed by plain chest X-ray film 2. uncontrollable malignancy

Design outcomes

Primary

Measure	Time frame
Clinical data include exacerbating factor, pulmonary functions, chest images, QOL, responses to the treatments, and biomarkers (cytokines, lipid mediators, cell functions, genetic polymorphisms) in biosamples peripheral blood cells, urine, sputum, exhaled air, exhaled air condensate, and tissue specimens will be determined.	—

Countries

Japan

Contacts

Public ContactHiroki Kabata

Keio University School of Medicine Division of pulmonary medicine

kabata.h@keio.jp03-3353-1211

Outcome results